ES2562643T5 - Conjugado de naloxol-peg cristalino - Google Patents

Conjugado de naloxol-peg cristalino Download PDF

Info

Publication number
ES2562643T5
ES2562643T5 ES11829686T ES11829686T ES2562643T5 ES 2562643 T5 ES2562643 T5 ES 2562643T5 ES 11829686 T ES11829686 T ES 11829686T ES 11829686 T ES11829686 T ES 11829686T ES 2562643 T5 ES2562643 T5 ES 2562643T5
Authority
ES
Spain
Prior art keywords
naloxol
salt
mpeg7
solid
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11829686T
Other languages
English (en)
Spanish (es)
Other versions
ES2562643T8 (es
ES2562643T3 (es
Inventor
Bengt Leonard Åslund
Carl-Johan Aurell
Martin Hans Bohlin
Tesfai Sebhatu
Bo Ingvar Ymen
Eric Thomas Healy
David Richard Jensen
David Thomas Jonaitis
Stephan Parent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Nektar Therapeutics
Original Assignee
AstraZeneca AB
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45893441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2562643(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB, Nektar Therapeutics filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2562643T3 publication Critical patent/ES2562643T3/es
Publication of ES2562643T5 publication Critical patent/ES2562643T5/es
Publication of ES2562643T8 publication Critical patent/ES2562643T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/06Oxalic acid
    • C07C55/07Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04Salts; Organic complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Emergency Medicine (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
ES11829686T 2010-09-30 2011-09-29 Conjugado de naloxol-peg cristalino Active ES2562643T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38850110P 2010-09-30 2010-09-30
US388501P 2010-09-30
PCT/SE2011/051161 WO2012044243A1 (en) 2010-09-30 2011-09-29 Crystalline naloxol-peg conjugate

Publications (3)

Publication Number Publication Date
ES2562643T3 ES2562643T3 (es) 2016-03-07
ES2562643T5 true ES2562643T5 (es) 2019-05-24
ES2562643T8 ES2562643T8 (es) 2022-07-12

Family

ID=45893441

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15188944T Active ES2819305T3 (es) 2010-09-30 2011-09-29 Combinación de un conjugado de naloxol-peg y un agonista opioide
ES11829686T Active ES2562643T5 (es) 2010-09-30 2011-09-29 Conjugado de naloxol-peg cristalino

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES15188944T Active ES2819305T3 (es) 2010-09-30 2011-09-29 Combinación de un conjugado de naloxol-peg y un agonista opioide

Country Status (39)

Country Link
US (2) US9012469B2 (zh)
EP (2) EP2621496B2 (zh)
JP (1) JP6034789B2 (zh)
KR (1) KR101791724B1 (zh)
CN (1) CN103237547B (zh)
AR (1) AR083268A1 (zh)
AU (1) AU2011307608B8 (zh)
BR (1) BR112013007113B1 (zh)
CA (1) CA2812649C (zh)
CL (1) CL2013000866A1 (zh)
CO (1) CO6700851A2 (zh)
CR (1) CR20130146A (zh)
CU (1) CU24317B1 (zh)
DK (1) DK2621496T4 (zh)
EA (1) EA023929B1 (zh)
EC (1) ECSP13012531A (zh)
ES (2) ES2819305T3 (zh)
GT (1) GT201300084A (zh)
HK (1) HK1187248A1 (zh)
HR (1) HRP20151420T4 (zh)
HU (1) HUE026726T2 (zh)
IL (1) IL225308A0 (zh)
ME (1) ME02313B (zh)
MX (1) MX2013003587A (zh)
MY (1) MY173890A (zh)
NI (1) NI201300034A (zh)
NZ (1) NZ609874A (zh)
PE (1) PE20140636A1 (zh)
PL (1) PL2621496T5 (zh)
PT (1) PT2621496E (zh)
RS (1) RS54488B8 (zh)
SA (1) SA111320808B1 (zh)
SG (1) SG188474A1 (zh)
SI (1) SI2621496T2 (zh)
SM (1) SMT201600004B (zh)
TW (1) TWI518088B (zh)
UA (1) UA112847C2 (zh)
UY (1) UY33643A (zh)
WO (1) WO2012044243A1 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2621496T5 (pl) 2010-09-30 2019-05-31 Astrazeneca Ab Krystaliczny koniugat naloksol-peg
JP6384964B2 (ja) * 2012-10-30 2018-09-05 ネクター セラピューティクス オピオイド作動薬としてのα−6−MPEG6−O−ヒドロキシコドンの固体塩およびその使用
KR20200045010A (ko) * 2015-03-10 2020-04-29 로드스 테크놀로지즈 부프레노르핀의 아세테이트 염 및 부프레노르핀의 제조 방법
CN107033154B (zh) 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN107033155B (zh) * 2016-02-04 2019-04-26 国药集团国瑞药业有限公司 一种吗啡酮类化合物的立体选择性还原方法
EP3228307A1 (en) 2016-04-05 2017-10-11 Sandoz Ag Solid dispersion comprising opioid antagonists
CN107303392A (zh) * 2016-04-19 2017-10-31 石家庄蒎格医药科技有限公司 一种聚乙二醇-纳洛酮组合物及应用
US11077103B2 (en) * 2016-11-23 2021-08-03 Aurobindo Pharma Ltd. Naloxegol oxalate and solid dispersion thereof
US11373198B2 (en) * 2016-12-02 2022-06-28 Honda Motor Co., Ltd. Evaluation device, evaluation method, and evaluation program
WO2019058387A1 (en) * 2017-09-19 2019-03-28 Msn Laboratories Private Limited, R&D Center IMPROVED PROCESS FOR THE PREPARATION OF (5Α, 6Α) -17-ALLYL-6- (2,5,8,11,14,17,20-HEPTAOXADOCOSAN-22-YLOXY) -4,5-EPOXYMORPHINANE-3,14-DIOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
CN114137133B (zh) * 2021-12-03 2023-06-09 北京尚修堂医药科技有限公司 一种纳洛醇-peg衍生物有关物质的检测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507136A (en) 1949-02-19 1950-05-09 New York Quinine And Chemical Alkaloid purification
CA2145207A1 (en) * 1992-09-21 1994-03-22 Bo-Yi Qin Methods for identifying and using low/non-addictive opioid analgesics
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
EP1355671A2 (en) 2000-11-30 2003-10-29 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of triazine derivatives
ATE337313T1 (de) 2000-12-22 2006-09-15 Smithkline Beecham Plc 5-4'-2'-(n-methyl-n-(2-pyridyl)amino) ethoxy)benzyl)thiazolidin-2,4-dion mesylatsalz
CA2437989A1 (en) 2001-02-20 2002-08-29 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6756354B2 (en) 2001-09-05 2004-06-29 Deanna Jean Nelson Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates
MXPA04003597A (es) 2001-10-18 2004-07-30 Nektar Therapeutics Al Corp Conjugados polimericos de antagonistas opiaceos.
WO2003037384A2 (en) 2001-10-29 2003-05-08 Nektar Therapeutics Al, Corporation Polymer conjugates of protein kinase c inhibitors
WO2003037385A1 (en) 2001-10-30 2003-05-08 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of retinoic acid
DK2425824T5 (en) * 2002-04-05 2018-02-12 Mundipharma As Pharmaceutical preparation containing oxycodone and naloxone
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
US7405198B2 (en) 2003-11-24 2008-07-29 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
PL1694363T3 (pl) * 2003-12-16 2014-07-31 Nektar Therapeutics Monodyspersyjne kompozycje PEGylowanego naloksolu
US8320574B2 (en) * 2006-04-20 2012-11-27 Hewlett-Packard Development Company, L.P. Methods and systems for reducing acoustic echoes in communication systems
AU2007240680B2 (en) 2006-04-21 2013-05-02 Nektar Therapeutics Stereoselective reduction of a morphinone
MX2009004965A (es) * 2006-11-07 2009-06-05 Nektar Therapeutics Al Corp Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides.
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
CA2723685C (en) * 2008-05-07 2016-09-27 Nektar Therapeutics Oral administration of peripherally-acting opioid antagonists
MX2012000980A (es) 2009-07-21 2012-06-12 Nektar Therapeutics Conjugados de agonistas de oligómeros-opioides.
PL2621496T5 (pl) 2010-09-30 2019-05-31 Astrazeneca Ab Krystaliczny koniugat naloksol-peg

Also Published As

Publication number Publication date
PT2621496E (pt) 2016-02-01
BR112013007113B1 (pt) 2020-09-24
IL225308A0 (en) 2013-06-27
US9012469B2 (en) 2015-04-21
AU2011307608A8 (en) 2015-08-27
EP2621496A4 (en) 2014-09-24
US20150283257A1 (en) 2015-10-08
TW201307356A (zh) 2013-02-16
RS54488B8 (sr) 2022-11-30
CN103237547B (zh) 2015-10-07
ES2819305T8 (es) 2022-05-26
HUE026726T2 (en) 2016-07-28
MY173890A (en) 2020-02-26
AU2011307608B8 (en) 2015-08-27
PL2621496T5 (pl) 2019-05-31
EA023929B1 (ru) 2016-07-29
CN103237547A (zh) 2013-08-07
RS54488B2 (sr) 2019-03-29
MX2013003587A (es) 2013-05-31
GT201300084A (es) 2015-01-16
EP2992903B8 (en) 2022-06-08
HRP20151420T1 (hr) 2016-01-29
CA2812649C (en) 2016-03-01
SMT201600004B (it) 2016-02-25
BR112013007113A2 (pt) 2017-07-25
AR083268A1 (es) 2013-02-13
RS54488B1 (en) 2016-06-30
ME02313B (me) 2016-06-20
ES2562643T8 (es) 2022-07-12
TWI518088B (zh) 2016-01-21
NZ609874A (en) 2014-10-31
EP2621496B2 (en) 2018-12-12
KR20130135844A (ko) 2013-12-11
EP2992903B1 (en) 2020-07-15
EP2621496B1 (en) 2015-12-16
CU20130047A7 (es) 2013-08-29
HRP20151420T4 (hr) 2019-04-05
CL2013000866A1 (es) 2013-08-30
AU2011307608A1 (en) 2013-05-02
EA201300423A1 (ru) 2013-09-30
SI2621496T2 (sl) 2019-04-30
DK2621496T4 (en) 2019-03-18
UA112847C2 (uk) 2016-11-10
SI2621496T1 (sl) 2016-02-29
CR20130146A (es) 2013-05-15
DK2621496T3 (en) 2016-01-18
WO2012044243A1 (en) 2012-04-05
PE20140636A1 (es) 2014-06-18
PL2621496T3 (pl) 2016-05-31
ES2562643T3 (es) 2016-03-07
CU24317B1 (es) 2018-02-08
EP2621496A1 (en) 2013-08-07
ECSP13012531A (es) 2013-06-28
SA111320808B1 (ar) 2014-12-15
US20150038524A1 (en) 2015-02-05
KR101791724B9 (ko) 2022-06-16
AU2011307608B2 (en) 2015-04-09
JP2013538849A (ja) 2013-10-17
CO6700851A2 (es) 2013-06-28
SG188474A1 (en) 2013-05-31
EP2992903A1 (en) 2016-03-09
NI201300034A (es) 2014-01-23
ES2819305T3 (es) 2021-04-15
UY33643A (es) 2012-04-30
JP6034789B2 (ja) 2016-11-30
HK1187248A1 (zh) 2014-04-04
CA2812649A1 (en) 2012-04-05
KR101791724B1 (ko) 2017-10-30
US9149539B1 (en) 2015-10-06

Similar Documents

Publication Publication Date Title
ES2562643T5 (es) Conjugado de naloxol-peg cristalino
ES2928586T3 (es) Fenilacetato de L-ornitina y métodos para elaborar el mismo
ES2694787T3 (es) Formas sólidas de un inhibidor selectivo de CDK4/6
ES2765811T5 (es) Forma cristalina de bromuro de (R)-n-metilnaltrexona y sus usos
ES2277301T3 (es) Solvato de hemitartrato de zolpidem.
BRPI0807974B1 (pt) Forma de sal cristalino, composiçao farmaceutica, processo para a preparaqao de um sal cristalino, aduto e uso da forma de sal cristalino
US20120165260A2 (en) Crystalline ezatiostat hydrochloride ansolvate
RU2476440C2 (ru) Кристаллические формы мононатриевой соли d-изоглутамил-d-триптофана
EP2576591A2 (en) Tablet formulation of ezatiostat
NZ759132B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
NZ719970A (en) Solid forms of { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, compositions, and uses thereof